resTORbio Reports First Quarter 2018 Financial Results
Last patient dosed in Phase 2b trial; topline data now expected in third quarter of 2018 BOSTON, May 10, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer …